FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
The prevalence and significance of genetic abnormalities in older patients with acute myeloid leukemia (AML) are unknown. Polymerase chain reactions and single-stranded conformational polymorphism analyses were used to examine 140 elderly AML patients enrolled in the Southwest Oncology Group study 9031 for FLT3, RAS, and TP53 mutations, which were found in 34%, 19%, and 9% of patients, respectively. All but one of the FLT3 (46 of 47) mutations were internal tandem duplications (ITDs) within exons 11 and 12. In the remaining case, a novel internal tandem triplication was found in exon 11. FLT3 ITDs were associated with higher white blood cell counts, higher peripheral blast percentages, normal cytogenetics, and less disease resistance. All RAS mutations (28 of 28) were missense point mutations in codons 12, 13, or 61. RASmutations were associated with lower peripheral blast and bone marrow blast percentages. Only 2 of 47 patients with FLT3 ITDs also had a RAS mutation, indicating a significant negative association between FLT3 and RAS mutations (P = .0013). Most TP53 mutations (11 of 12) were missense point mutations in exons 5 to 8 and were associated with abnormal cytogenetics, especially abnormalities in both chromosomes 5 and 7. FLT3 and RAS mutations were not associated with inferior clinical outcomes, but TP53mutations were associated with a worse overall survival (median 1 versus 8 months, P = .0007). These results indicate that mutations in FLT3, RAS, or TP53 are common in older patients with AML and are associated with specific AML phenotypes as defined by laboratory values, cytogenetics, and clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K., & Sekiya, T. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2766 · Cited by 3,610
Cancer—Principles & Practice of Oncology
Rhoads, J. E. (1983) · PubMed Central · Cited by 1,466
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., & Misawa, S. (1996) · PubMed · Cited by 1,347
p14ARF links the tumour suppressors RB and p53
Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., & Vousden, K. H. (1998) · Nature · doi:10.1038/25867 · Cited by 918
Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I.-M., Head, D. R., Appelbaum, F. R., & Willman, C. L. (1997) · Blood · doi:10.1182/blood.v89.9.3323 · Cited by 859
Self-citationA Southwest Oncology Group study
Jenkins, T. R., Tangen, C. M., Macdonald, J. S., Weiss, G. R., Chapman, R. M., & Hantel, A. (1993) · Cited by 773
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 757
PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA.
Hayashi, K. (1991) · Genome Research · doi:10.1101/gr.1.1.34 · Cited by 756
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
p19ARF links the tumour suppressor p53 to Ras
Palmero, I., Pantoja, C., & Serrano, M. (1998) · Nature · doi:10.1038/25870 · Cited by 615
Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 591
Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H., & Naoe, T. (2000) · Oncogene · doi:10.1038/sj.onc.1203354 · Cited by 579
Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S., Okuda, T., Sonoda, Y., Abe, T., Kahsima, K., Matsuo, Y., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400812 · Cited by 455
Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia
Kiyoi, H., Naoe, T., Yokota, S., Nakao, M., Minami, S., Kuriyama, K., Takeshita, A., Saito, K., Hasegawa, S., Shimodaira, S., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400756 · Cited by 344
Godwin, J. E., Kopecky, K. J., Head, D. R., Willman, C. L., Leith, C. P., Hynes, H. E., Balcerzak, S. P., & Appelbaum, F. R. (1998) · Blood · doi:10.1182/blood.v91.10.3607 · Cited by 312
Self-citationRombouts, W., Blokland, I., Löwenberg, B., & Ploemacher, R. (2000) · Leukemia · doi:10.1038/sj.leu.2401731 · Cited by 277
Horiike, S., Yokota, S., Nakao, M., Iwai, T., Sasai, Y., Kaneko, H., Taniwaki, M., Kashima, K., Fujii, H., Abe, T., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400770 · Cited by 209
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia
Neubauer, A., Dodge, R., George, S., Davey, F., Silver, R., Schiffer, C., Mayer, R., Ball, E., Wurster-Hill, D., & Bloomfield, C. (1994) · Blood · doi:10.1182/blood.v83.6.1603.1603 · Cited by 199
Xu, F., Taki, T., Yang, H. W., Hanada, R., Hongo, T., Ohnishi, H., Kobayashi, M., Bessho, F., Yanagisawa, M., & Hayashi, Y. (1999) · British Journal of Haematology · doi:10.1111/j.1365-2141.1999.01284.x · Cited by 178
P53 gene mutations in acute myeloid leukemia with 17p monosomy
Fenaux, P., Jonveaux, P., Quiquandon, I., Lai, J., Pignon, J., Loucheux-Lefebvre, M., Bauters, F., Berger, R., & Kerckaert, J. (1991) · Blood · doi:10.1182/blood.v78.7.1652.1652 · Cited by 175
Iwai, T., Yokota, S., Nakao, M., Okamoto, T., Taniwaki, M., Onodera, N., Watanabe, A., Kikuta, A., Tanaka, A., Asami, K., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401241 · Cited by 173
Dosil, M., Wang, S., & Lemischka, I. R. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6572 · Cited by 172
The 3Rs of life: Ras, Raf and growth regulation
Moodie, S. A., & Wolfman, A. (1994) · Trends in Genetics · doi:10.1016/0168-9525(94)90147-3 · Cited by 163
N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance
Radich, J., Kopecky, K., Willman, C., Weick, J., Head, D., Appelbaum, F., & Collins, S. (1990) · Blood · doi:10.1182/blood.v76.4.801.801 · Cited by 161
Self-citationMutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS- derived leukemia
Sugimoto, K., Hirano, N., Toyoshima, H., Chiba, S., Mano, H., Takaku, F., Yazaki, Y., & Hirai, H. (1993) · Blood · doi:10.1182/blood.v81.11.3022.3022 · Cited by 123
Nakano, Y., Kiyoi, H., Miyawaki, S., Asou, N., Ohno, R., Saito, H., & Naoe, T. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01256.x · Cited by 110
Agnès, F., Shamoon, B., Dina, C., Rosnet, O., Birnbaum, D., & Galibert, F. (1994) · Gene · doi:10.1016/0378-1119(94)90021-3 · Cited by 108
Revised classification of acute myeloid leukemia.
Head, D. R. (1996) · PubMed · Cited by 100
Lavagna, C., Marchetto, S., Birnbaum, D., & Rosnet, O. (1998) · Leukemia · doi:10.1038/sj.leu.2400921 · Cited by 100
Motor performance of children during treatment for acute lymphoblastic leukemia
Reinders‐Messelink, H. A., Schoemaker, M. M., Snijders, T. A. B., G�eken, L., van den Briel, M. M., B�kkerink, J. P. M., & Kamps, W. A. (1999) · Medical and Pediatric Oncology · doi:10.1002/(sici)1096-911x(199912)33:6<525::aid-mpo1>3.0.co;2-8 · Cited by 88
Rottapel, R. K., Turck, C. W., Castéran, N., Liu, X., Birnbaum, D., Pawson, T. J., & Dubreuil, P. C. (1994) · PubMed · Cited by 73
Analysis of p53 gene mutations in acute myeloid leukemia
Trecca, D., Longo, L., Biondi, A., Cro, L., Calori, R., Grignani, F., Maiolo, A. T., Pelicci, P. G., & Neri, A. (1994) · American Journal of Hematology · doi:10.1002/ajh.2830460409 · Cited by 35
Vingron, M., Nordheim, A., & Müller, R. (1988) · PubMed · Cited by 17
Radich, J. P., Kopecky, K. J., Appelbaum, F. R., Willman, C. L., & Collins, S. (1992) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199209053564 · Cited by 11
Self-citationJehn, U. (1994) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199409073785 · Cited by 4
Cited by
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
Magee, J. A., Piskounova, E., & Morrison, S. J. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.003 · Cited by 1,101
Metadata
- Authors
- Stirewalt, D. L., Kopecky, K. J., Meshinchi, S., Appelbaum, F. R., Slovak, M. L., Willman, C. L., & Radich, J. P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-06-01
- Volume
- 97
- Issue
- 11
- Pages
- 3589-3595
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2078481381
- Cited by
- 431
- References
- 38
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.